FENC (Fennec Pharmaceuticals) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FENC Fennec Pharmaceuticals Inc FENC
54 GF Score
Price $10.50
GF Value $10.16
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Short-term investments?

Short-term investments only applies to insurance companies.

FENC
54GF Score
Fennec Pharmaceuticals Inc FENC
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of $10.50 is trading 3.3% above its estimated GF Value™ of $10.16. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for FENC:

  • Short-term investments:
  • GF Value™: $10.16 vs. price of $10.50 (3.3% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges RV41:GermanyFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for FENC

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.50
Price
$10.16
GF Value